VYLODIA Trademark

Trademark Overview

On Monday, March 23, 2020, a trademark application was filed for VYLODIA with the United States Patent and Trademark Office. The USPTO has given the VYLODIA trademark a serial number of 88844769. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Thursday, July 6, 2023. This trademark is owned by Omeros Corporation. The VYLODIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for complement-mediated diseases, addiction and oncology
vylodia

General Information

Serial Number88844769
Word MarkVYLODIA
Filing DateMonday, March 23, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateThursday, July 6, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 26, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for complement-mediated diseases, addiction and oncology
Translation of Words in MarkThe wording "VYLODIA" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 26, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOmeros Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98119
Party NameOmeros Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98119

Trademark Events

Event DateEvent Description
Friday, July 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 6, 2023SOU EXTENSION 5 GRANTED
Wednesday, June 28, 2023SOU EXTENSION 5 FILED
Thursday, July 6, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 28, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 9, 2023SOU EXTENSION 4 GRANTED
Monday, January 9, 2023SOU EXTENSION 4 FILED
Monday, January 9, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 7, 2022SOU EXTENSION 3 GRANTED
Wednesday, September 7, 2022SOU EXTENSION 3 FILED
Wednesday, September 7, 2022SOU TEAS EXTENSION RECEIVED
Saturday, February 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 24, 2022SOU EXTENSION 2 GRANTED
Thursday, February 24, 2022SOU EXTENSION 2 FILED
Thursday, February 24, 2022SOU TEAS EXTENSION RECEIVED
Thursday, August 26, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 24, 2021SOU EXTENSION 1 GRANTED
Tuesday, August 24, 2021SOU EXTENSION 1 FILED
Tuesday, August 24, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 23, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 26, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 26, 2021PUBLISHED FOR OPPOSITION
Wednesday, January 6, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, December 21, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 8, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 7, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 7, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, June 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, June 14, 2020NON-FINAL ACTION E-MAILED
Sunday, June 14, 2020NON-FINAL ACTION WRITTEN
Saturday, June 13, 2020ASSIGNED TO EXAMINER
Thursday, March 26, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 26, 2020NEW APPLICATION ENTERED

Related Keywords

vylodia addiction oncology diseases mediated preparations complement pharmaceutical